Apimeds Pharmaceuticals
Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing Apitox, an intradermally administered, purified bee venom-based biologic licensed from Apimeds Korea. Apitox is being evaluated as a potential treatment for knee osteoarthritis in patients unresponsive to conventional therapies. Apimeds Pharmaceuticals is also exploring Apitox's application in managing symptoms of multiple sclerosis.
No technologies detected yet for this company.
Frequently Asked Questions
What technologies does Apimeds Pharmaceuticals use?+
We have not yet detected technologies for Apimeds Pharmaceuticals.
What industry is Apimeds Pharmaceuticals in?+
Apimeds Pharmaceuticals operates in the Biotechnology industry.
Where is Apimeds Pharmaceuticals based?+
Apimeds Pharmaceuticals is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026